Claims for Patent: 9,260,724

Summary for Patent: 9,260,724

Title:	Optimization of expression of parvoviral rep and cap proteins in insect cells
Abstract:	The present invention relates to the improved production of recombinant parvoviral virions in insect cells. In particular, the invention relates to an improved process for the production of recombinant parvoviral virions in insect cells, wherein the full/empty parvoviral virion ratio is increased. The invention also relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral Rep proteins that increase the productivity of parvoviral vectors.
Inventor(s):	Bakker; Andrew Christian (Almere, NL), Hermens; Wilhelmus Theodorus Johannes Maria Christiaan Maria Christ (Almere, NL), Noordman; Yvet (Utrecht, NL)
Assignee:	UNIQURE IP B.V. (Amsterdam, NL)
Application Number:	14/149,953
Patent Claims:	1. A method for the production of a recombinant parvoviral virion which decreases the total:full virion particle ratio, wherein the method comprises culturing an insect cell comprising one or more nucleic acid constructs which comprise: (a) a nucleotide sequence comprising a transgene that is flanked by at least one parvoviral inverted terminal repeat (ITR) nucleotide sequence; (b) a first expression cassette comprising a nucleotide sequence encoding parvoviral Rep proteins Rep78 and Rep52, which nucleotide sequence is operably linked to a first promoter that is capable of driving expression of the Rep78 and Rep52 proteins in the insect cell and wherein the nucleotide sequence encoding the parvoviral Rep proteins is a single open reading frame encoding Rep78 and Rep52 proteins; and (c) a second expression cassette comprising a nucleotide sequence encoding parvoviral capsid proteins which is operably linked to a second promoter that is capable of driving expression of the capsid proteins in the insect cell; under conditions conducive to the expression of the Rep proteins and the capsid proteins wherein expression of the Rep 78 and Rep52 proteins is greater than expression of the capsid proteins; wherein (i) the first and second expression cassettes are present on a single nucleic acid construct and are present in equimolar amounts in the insect cell, (ii) the ratio of the expression of Rep78 and Rep52 proteins to the expression of capsid proteins is regulated by one or more of the following structures or conditions: (A) the first promoter is stronger than the second promoter; (B) more and/or stronger enhancer elements are present in the first expression cassette as compared to the second expression cassette; (C) the nucleotide sequence encoding the Rep78 and the Rep52 proteins has a higher codon adaptation index compared to the nucleotide sequence encoding the capsid proteins; (D) the Rep78 and the Rep52 proteins are temperature optimized; (E) the Rep78 and the Rep52 proteins are variants with altered amino acid sequences as compared to the sequences of corresponding wild-type Rep78 and Rep52 proteins, wherein the altered sequences result in increased Rep78 and Rep52 protein function manifest as increased adeno-associated virus (AAV) production in the insect cell; and/or (F) the first promoter is as strong as the second promoter, one or more of structures or conditions (B)-(E) is present, and the insect cell comprises an additional nucleotide sequence encoding for an additional Rep protein, resulting in expression of the Rep78 and Rep52 proteins that is greater than expression of the capsid proteins, thereby decreasing the total:full virion particle ratio compared to a method in which the expression of the Rep78 and the Rep52 proteins is not greater than the expression of the capsid proteins. 2. The method according to claim 1, wherein the initiation codon for translation of the parvoviral Rep78 protein is a suboptimal initiation codon. 3. The method according to claim 2, wherein the suboptimal initiation codon is selected from the group consisting of ACG, TTG, CTG and GTG. 4. The method according to claim 3, wherein the suboptimal initiation codon is ACG or CTG. 5. The method according to claim 1, wherein possible false translation initiation sites in the Rep protein coding sequences other than the Rep78 and Rep52 translation initiation sites, are eliminated. 6. The method according to claim 1, wherein the nucleotide sequence encoding the parvoviral capsid proteins of (c) comprises an open reading frame (ORF) comprising nucleotide sequences encoding the VP1, VP2 and VP3 capsid proteins. 7. The method according to claim 6, wherein (i) at least one ORF comprising nucleotide sequences encoding VP1, VP2 or VP3 capsid proteins does not comprise an artificial intron, or (ii) at least one ORF comprising a nucleotide sequence encoding said Rep78 and Rep52 proteins does not comprise an artificial intron. 8. The method according to claim 7, wherein: (A) no ORF comprising nucleotide sequences encoding the VP1, VP2 and VP3 capsid proteins comprises an artificial intron; and/or (B) no ORF comprising nucleotide sequences encoding said Rep78 and Rep52 proteins comprises an artificial intron. 9. The method according to claim 1, wherein the first promoter or the second promoter is selected from the group consisting of (a) a PolH promoter, (b) p10 promoter, (c) a basic promoter, (d) an inducible promoter, (e) an E1 promoter, and (f) a deltaE1 promoter. 10. The method according to claim 9, wherein (a) the first promoter is: (i) a PolH promoter, (ii) p10 promoter or (iii) basic promoter, and (b) the second promoter is: (i) a deltaE1 promoter or (ii) an E1 promoter. 11. The method according to claim 1, wherein the first expression cassette comprises at least one baculovirus enhancer element and/or at least one ecdysone responsive element. 12. The method according to claim 11, wherein the enhancer element is selected from the group consisting of hr1, hr2, hr3, hr4 and hr5. 13. The method according to claim 1, wherein the parvoviral ITR sequence, the parvoviral Rep78 and Rep52 proteins and/or the parvoviral capsid proteins are from an AAV. 14. The method according to claim 1, further comprising a step of recovering the recombinant parvoviral virion from the culture. 15. A nucleic acid construct comprising a first and a second expression cassette as defined in claim 1, wherein: (a) the first promoter is a p10 promoter and the second promoter is a PolH promoter or a 4.times.Hsp27 EcRE+minimal Hsp70 promoter; (b) the first promoter is a PolH promoter and the second promoter is a deltaIE1 or an IE1 promoter; (c) the first promoter is a p10 promoter and the second promoter is a deltaIE1 or an IE1 promoter; or (d) the first promoter is a PolH promoter and the second promoter is a PolH promoter, and wherein the first expression cassette optionally comprises an enhancer element. 16. A kit comprising (a) a first nucleic acid construct comprising: (i) a first expression cassette comprising a nucleotide sequence encoding parvoviral Rep proteins Rep78 and Rep52 which is operably linked to a first promoter that is capable of driving expression of the Rep78 or Rep52 protein in a host insect cell and wherein the nucleotide sequence encoding the parvoviral Rep protein is a single open reading frame encoding Rep78 and Rep52 proteins; and (ii) a second expression cassette comprising a nucleotide sequence encoding parvoviral capsid proteins which is operably linked to a second promoter that is capable of driving expression of the capsid proteins in the insect cell; wherein expression of Rep78 and Rep52 proteins in insect cells is regulated by one or more of the following structures or conditions: (A) the first promoter is stronger than the second promoter; (B) the first expression cassette comprises more and/or stronger enhancer elements as compared to the second expression cassette; (C) the nucleotide sequence encoding the Rep78 and the Rep52 proteins has a higher codon adaptation index compared to the nucleotide sequence encoding the capsid proteins; (D) the Rep78 and the Rep52 proteins are temperature optimized; (E) the Rep78 and the Rep52 proteins are variants with altered amino acid sequences as compared to the sequences of corresponding wild-type Rep78 and Rep52 proteins, wherein the altered sequences result in increased Rep78 and Rep52 protein function manifest as increased adeno-associated virus (AAV) production in the insect cell; and/or (F) the first promoter is as strong as the second promoter and one or more of structures or conditions (B)-(E) is present; such that, when expressed in the insect cell, expression of the Rep78 and the Rep52 proteins is greater than expression of the capsid proteins, which decreases the total:full virion particle ratio compared to a method in which the expression of the Rep78 and the Rep52 proteins is not greater than the expression of the capsid proteins, wherein when the first promoter is as strong as the second promoter and one or more of (B)-(E) is present, then the insect cell comprises an additional nucleotide sequence encoding an additional Rep protein, and (b) a second nucleic acid construct comprising a nucleotide sequence encoding a multiple cloning site for a transgene, which site is flanked by at least one parvoviral ITR nucleotide sequence, and which transgene is operably linked to a promoter capable of driving its expression in a host insect cell. 17. The kit according to claim 16, wherein the initiation codon for translation of the parvoviral Rep78 protein is a suboptimal initiation codon. 18. The kit according to claim 17, wherein the suboptimal initiation codon is selected from the group consisting of ACG, TTG, CTG and GTG. 19. The kit according to claim 18, wherein the suboptimal initiation codon is ACG or CTG. 20. The kit according to claim 16, wherein possible false translation initiation sites in the Rep protein coding sequences other than the Rep78 and Rep52 translation initiation sites, are eliminated. 21. An insect cell comprising one or more nucleic acid constructs, which comprise: (a) a nucleotide sequence comprising a transgene that is flanked by at least one parvoviral ITR nucleotide sequence; (b) a first expression cassette comprising a nucleotide sequence encoding parvoviral Rep proteins Rep78 and Rep52, which nucleotide sequence is operably linked to a first promoter that is capable of driving expression of the Rep78 and Rep52 proteins in the insect cell and wherein the nucleotide sequence encoding the parvoviral Rep proteins is a single open reading frame encoding Rep78 and Rep52 proteins; and (c) a second expression cassette comprising a nucleotide sequence encoding parvoviral capsid proteins which is operably linked to a second promoter that is capable of driving expression of the capsid proteins in the insect cell; wherein (i) the first and second expression cassettes are present on a single nucleic acid construct and are present in equimolar amounts in the insect cell, and (ii) the ratio of the expression of Rep78 and Rep52 proteins to the expression of capsid proteins in said cell is regulated by one or more of the following structures or conditions: (A) the first promoter is stronger than the second promoter; (B) more and/or stronger enhancer elements are present in the first expression cassette as compared to the second expression cassette; (C) the nucleotide sequence encoding the Rep78 and the Rep52 proteins has a higher codon adaptation index compared to the nucleotide sequence encoding the capsid proteins; (D) the Rep78 and the Rep52 proteins are temperature optimized; (E) the Rep78 and the Rep52 proteins are variants with altered amino acid sequences as compared to the sequences of corresponding wild-type Rep78 and Rep52 proteins, wherein the altered sequences result in increased Rep78 and Rep52 protein function manifest as increased adeno-associated virus (AAV) production in the insect cell; and/or (F) the first promoter is as strong as the second promoter, one or more of structures or conditions (B)-(E) is present, and the insect cell comprises an additional nucleotide sequence encoding for an additional Rep protein, such that, when expressed in the insect cell, expression of the Rep78 and Rep52 proteins is greater than expression of the capsid proteins, which decreases the total:full virion particle ratio compared to a method in which the expression of the Rep78 and the Rep52 proteins is not greater than the expression of the capsid proteins. 22. The insect cell according to claim 21, wherein the initiation codon for translation of the parvoviral Rep78 protein is a suboptimal initiation codon. 23. The insect cell according to claim 22, wherein the suboptimal initiation codon is selected from the group consisting of ACG, TTG, CTG and GTG. 24. The insect cell according to claim 23, wherein the suboptimal initiation codon is ACG or CTG. 25. The insect cell according to claim 21, wherein possible false translation initiation sites in the Rep protein coding sequences other than the Rep78 and Rep52 translation initiation sites, are eliminated.

Details for Patent 9,260,724

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2028-02-19
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2028-02-19
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2028-02-19